Advanced Renal Cell Carcinoma Lenvatinib in Combination with Everolimus is approved as a Second-line Therapy

被引：0
|
作者：
Krampe-Scheidler, Anne
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 10期
关键词：
INHIBITOR; E7080;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：666 / 667
页数：2
相关论文
共 50 条
  • [31] Current Aspects of Second-Line and Sequence Therapy of Metastatic Renal Cell Carcinoma
    Gschwend, Juergen E.
    ONKOLOGIE, 2010, 33 : 10 - 11
  • [32] Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
    Mitsogiannis, Iraklis C.
    Mitsogianni, Maria
    Papathanassiou, Maria
    Anagnostou, Maria
    Tamposis, Ioannis
    Mitrakas, Lampros
    Samara, Maria
    Tzortzis, Vassilios
    Vlachostergios, Panagiotis J.
    JOURNAL OF KIDNEY CANCER AND VHL, 2022, 9 (03): : 29 - 40
  • [33] What Next? Choosing Second-Line Therapy in Progressive Renal Cell Carcinoma
    Bourlon, Maria T.
    Kessler, Elizabeth R.
    ONCOLOGY-NEW YORK, 2014, 28 (09): : 794 - 796
  • [34] Recommendations for the treatment of patients with advanced or metastatic renal cell cancer with the combination of lenvatinib and everolimus
    Grande, E.
    Glen, H.
    Aller, J.
    Argenziano, G.
    Lamas, M. J.
    Ruszniewski, P.
    Zamorano, J. L.
    Edmonds, K.
    Sarker, S.
    Staehler, M.
    Larkin, J.
    ONKOUROLOGIYA, 2020, 16 (04): : 61 - 81
  • [35] Lenvatinib in combination with everolimus in metastatic renal cell carcinoma resistant to antiangiogenic targeted therapy: an initial Russian experience
    Volkova, M. I.
    Evsyukova, O. I.
    Olshanskaya, A. S.
    Matveev, V. B.
    ONKOUROLOGIYA, 2018, 14 (01): : 76 - 86
  • [36] Renal-cell carcinoma - current options for the second-line treatment with specific focus on the role of everolimus
    Wysocki, Piotr J.
    Zolnierek, Jakub
    Krzemieniecki, Krzysztof
    Drosik, Kazimierz
    Potemski, Piotr
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (03): : 113 - 118
  • [37] COST OF CARE WITH EVEROLIMUS VERSUS AXITINIB FOR SECOND-LINE METASTATIC RENAL CELL CARCINOMA PATIENTS IN CANADA
    Perrin, A.
    Chua, A.
    Wang, X.
    Hurry, M.
    VALUE IN HEALTH, 2013, 16 (07) : A402 - A402
  • [38] A phase 2 trial of lenvatinib in combination with everolimus in patients with advanced or metastatic non-clear cell renal cell carcinoma
    Hutson, Thomas
    Xing, Dongyuan
    Dutcus, Corina
    Baig, Mahadi
    Fishman, Mayer
    BJU INTERNATIONAL, 2016, 118 : 14 - 15
  • [39] Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Hirano, Taishi
    Ogasawara, Naoyuki
    Chikui, Katsuaki
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Igawa, Tsukasa
    ANTICANCER RESEARCH, 2018, 38 (09) : 5387 - 5392
  • [40] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
12345